Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

46.51 +1.28 (+2.82%)
Streaming Delayed Price Updated: 9:45 AM EDT, Sep 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 75,650
Open 46.00
Bid (Size) 46.24 (100)
Ask (Size) 46.77 (200)
Prev. Close 45.23
Today's Range 45.84 - 47.52
52wk Range 29.45 - 60.91
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026 
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment... 
From Veracyte, Inc.
Via GlobeNewswire

Performance

YTD
+9.7%
+9.7%
1 Month
+7.7%
+7.7%
3 Month
-22.7%
-22.7%
6 Month
+52.8%
+52.8%
1 Year
+38.4%
+38.4%

More News

Read More
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow ↗
Via Chartmill
News headline image
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
From Veracyte, Inc.
Via GlobeNewswire
Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential ↗
Via Chartmill
Veracyte (NASDAQ:VCYT) Smashes Q2 Estimates but Full-Year Guidance Disappoints, Shares Fall ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout Setup ↗
Via Chartmill
News headline image
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Veracyte Announces Second Quarter 2026 Financial Results
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via GlobeNewswire
Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profile ↗
Via Chartmill
High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT) ↗
Via Chartmill
News headline image
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
From Veracyte
Via Business Wire
News headline image
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
From Veracyte, Inc.
Via Business Wire
News headline image
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
From USA News Group
Via GlobeNewswire

Frequently Asked Questions

Is Veracyte, Inc. - Common Stock publicly traded?
Yes, Veracyte, Inc. - Common Stock is publicly traded.
What exchange does Veracyte, Inc. - Common Stock trade on?
Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Veracyte, Inc. - Common Stock?
The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
What is the current price of Veracyte, Inc. - Common Stock?
The current price of Veracyte, Inc. - Common Stock is 46.51
When was Veracyte, Inc. - Common Stock last traded?
The last trade of Veracyte, Inc. - Common Stock was at 09/29/26 09:45 AM ET
What is the market capitalization of Veracyte, Inc. - Common Stock?
The market capitalization of Veracyte, Inc. - Common Stock is 3.14B
How many shares of Veracyte, Inc. - Common Stock are outstanding?
Veracyte, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.